


 中文标题

桂枝茯苓胶囊主要效应成分在比格犬体内的药代动力学

投稿时间：2011-03-16 责任编辑：马超一 [点此下载全文](#)

广告合作

引用本文：朱克近·孙晓萍·常秀娟·秦建平·王振中·董伟·桂枝茯苓胶囊主要效应成分在比格犬体内的药代动力学[J].中国中药杂志,2011,36(8):1015.

DOI: 10.4268/cjcm20110815

摘要点击次数: 435

全文下载次数: 132



作者中文名	作者英文名	单位中文名	单位英文名	E-Mail
朱克近	ZHU Kejin	江苏康缘药业股份有限公司, 江苏 连云港 222001 中药制药过程新技术国家重点实验 室, 江苏 连云港 222001 江苏省企业院士工作室, 江苏 连云 港 222001	Jiangsu Kanion Pharmaceutical Co.,Ltd., Lianyungang 222001, China State Key Laboratory of Pharmaceutical New-tech for Chinese Medicine, Lianyungang 222001, China Enterprises Academician Workstations in Jiangsu Province, Lianyungang 222001, China	
孙晓萍	SUN Xiaoping	江苏康缘药业股份有限公司, 江苏 连云港 222001 中药制药过程新技术国家重点实验 室, 江苏 连云港 222001 江苏省企业院士工作室, 江苏 连云 港 222001	Jiangsu Kanion Pharmaceutical Co.,Ltd., Lianyungang 222001, China State Key Laboratory of Pharmaceutical New-tech for Chinese Medicine, Lianyungang 222001, China Enterprises Academician Workstations in Jiangsu Province, Lianyungang 222001, China	
常秀娟	CHANG Xiujuan	江苏康缘药业股份有限公司, 江苏 连云港 222001 中药制药过程新技术国家重点实验 室, 江苏 连云港 222001 江苏省企业院士工作室, 江苏 连云 港 222001	Jiangsu Kanion Pharmaceutical Co.,Ltd., Lianyungang 222001, China State Key Laboratory of Pharmaceutical New-tech for Chinese Medicine, Lianyungang 222001, China Enterprises Academician Workstations in Jiangsu Province, Lianyungang 222001, China	
秦建平	QIN Jianping	江苏康缘药业股份有限公司, 江苏 连云港 222001 中药制药过程新技术国家重点实验 室, 江苏 连云港 222001 江苏省企业院士工作室, 江苏 连云 港 222001	Jiangsu Kanion Pharmaceutical Co.,Ltd., Lianyungang 222001, China State Key Laboratory of Pharmaceutical New-tech for Chinese Medicine, Lianyungang 222001, China Enterprises Academician Workstations in Jiangsu Province, Lianyungang 222001, China	
王振中	WANG Zhenzhong	江苏康缘药业股份有限公司, 江苏 连云港 222001 中药制药过程新技术国家重点实验 室, 江苏 连云港 222001 江苏省企业院士工作室, 江苏 连云 港 222001	Jiangsu Kanion Pharmaceutical Co.,Ltd., Lianyungang 222001, China State Key Laboratory of Pharmaceutical New-tech for Chinese Medicine, Lianyungang 222001, China Enterprises Academician Workstations in Jiangsu Province, Lianyungang 222001, China	
董伟	XIAO Wei	江苏康缘药业股份有限公司, 江苏 连云港 222001 中药制药过程新技术国家重点实验 室, 江苏 连云港 222001 江苏省企业院士工作室, 江苏 连云 港 222001	Jiangsu Kanion Pharmaceutical Co.,Ltd., Lianyungang 222001, China State Key Laboratory of Pharmaceutical New-tech for Chinese Medicine, Lianyungang 222001, China Enterprises Academician Workstations in Jiangsu Province, Lianyungang 222001, China	

基金项目:国家重大新药创制专项(2009ZX09504-004)

中文摘要:目的:研究桂枝茯苓胶囊中主要成分芍药苷、芍药内酯苷、苦杏仁苷在比格犬体内的药代动力学特征。方法:比格犬口服给予桂枝茯苓胶囊0.044 8.0.179 2 g · kg⁻¹后,取股静脉收集血浆样本,经固相萃取小柱富集后,HPLC-MS/MS检测血药浓度,DAS 2.0软件计算药代动力学参数。结果:芍药苷、芍药内酯苷、苦杏仁苷体内检测定量限分别为0.25,2.64,0.04 μg · L⁻¹,不同剂量下芍药苷^t 1/2 分别为4.33,3.62 h;苦杏仁苷^t 1/2 分别为6.16,5.91 h;各成分数体内AUC_{0-t}与剂量有较好相关性。结论:芍药苷、芍药内酯苷、苦杏仁苷在体内均有较高暴露量,可用二室模型来描述。

中文关键词:芍药苷 芍药内酯苷 苦杏仁苷 桂枝茯苓胶囊 药代动力学

Pharmacokinetics of Guizhi Fuling capsule in beagle dogs

Abstract:Objective : To investigate pharmacokinetic parameters of peoniflornin, albiflornin and amygdaloside after administration of Guizhi Fuling capsule in beagle dogs. Method : Plasma was collected from forelimb vein of Beagle dogs after oral administration of GuizhiFuling capsule. HPLC-MS/MS method was used to determine the concentrations of constituents in plasma. The pharmacokinetic parameters were analyzed by program DAS 2.0. Result : The limit of quantitation of peoniflornin, albiflornin and amygdaloside were 0.25, 2.64, 0.04 μg · L⁻¹, respectively. After administrated with different doses, half-life of peoniflornin in dogs were 4.33, 3.62 h, albiflornin were 6.16, 5.91 h, amygdaloside were 2.43, 1.32 h. The AUC_{0-t} of all components were related to dose. Conclusion : The pharmacokinetic course of peoniflornin, albiflornin and amygdaloside can be described by two-compartment model, and these components have high expose.

Keywords:peoniflornin albiflornin amygdaloside Guizhi Fuling capsule pharmacokinetics

[查看全文](#) [查看/发表评论](#) [下载PDF阅读器](#)